News
Press Release
Home>News>Press Release>Text

KN015 patent filed in China

Time:2014-12-31 Source:admin Print Font size:BigMiddleSmall

KN015 is a long-acting human follicle-stimulating hormone(FSH) used for infertility treatment.KN015 is proposed for ART programs only. Its indication is controlled ovarian stimulation (COS) in combination with a GnRH(Gonadotropin releasing hormone) antagonist for the development of multiple follicles in women participating in an Assisted Reproductive Technology (ART) program. Preclinical data demands a much longer in vivo half-life and a similar bio-acitivity comparing with Gonal-F.Due to its prolonged duration of FSH activity, a single subcutaneous injection of the recommended dose of KN015 may replace any daily rFSH preparation in a COS treatment cycle.

Alphamab already filed IND to CFDA in 2014. and the patent was filed recently in China.